Antiglucocorticoid and related treatments for psychosis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 1, 2016, Pages

  Garner, Belinda ^a   Phillips, Lisa J ^b   Bendall, Sarah ^c   Hetrick, Sarah E ^c  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Orygen The National Centre of Excellence in Youth Mental Health   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; AMINOGLUTETHIMIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CORTICOSTEROID; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DEXAMETHASONE; ETOMIDATE; GLUCOCORTICOID ANTAGONIST; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; NEUROLEPTIC AGENT; ORG 34116; PLACEBO; PRASTERONE; SPIRONOLACTONE; STEROID; UNCLASSIFIED DRUG; GLUCOCORTICOID;

AKATHISIA; ALLERGY; BRIEF PSYCHIATRIC RATING SCALE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COGNITION; CORTICOSTEROID THERAPY; DEPRESSION; DEPRESSIVE PSYCHOSIS; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSTONIA; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYMPTOM; FOLLOW UP; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HAMILTON DEPRESSION RATING SCALE; HIGH RISK PATIENT; HUMAN; HYPERKINESIA; INTERVENTION STUDY; MENTAL HEALTH; MENTAL PATIENT; META ANALYSIS; METABOLIC DISORDER; MONOTHERAPY; MOTOR DYSFUNCTION; NEGATIVE SYNDROME; PAIN; PARKINSONISM; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; WEIGHT GAIN; ANTAGONISTS AND INHIBITORS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PSYCHOTIC DISORDERS;

DEHYDROEPIANDROSTERONE; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; KETOCONAZOLE; MIFEPRISTONE; PITUITARY-ADRENAL SYSTEM; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84966425160     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006995.pub2     Document Type: Review

References (124)

1. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. Journal of Clinical Psychopharmacology 2001; Vol. 21, issue 5:516-21.
2. DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biological Psychiatry 2006; Vol. 60, issue 12:1343-9. [PUBMED: 16889757 ]
3. Carroll BJ, Rubin RT. Is mifepristone useful in psychotic depression? [comment]. Neuropsychophamacology 2006;12:2793-4. [PUBMED: 17109015 ]
4. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006; Vol. 31, issue 3:628-36.
5. Keller J, Schatzberg AF. Reply: Clinical and biological effects of mifepristone treatment for psychotic treatment. Neuropsychopharmacology 2006;3:628-36. [PUBMED: 16160710]
6. NCT00048269. HPA axis/dopamine interactions in psychotic depression. https://www.clinicaltrials.gov/ct/show/NCT00048269 (accessed 28 February 2012).
7. Gallagher P, Watson S, Dye CE, Young AH, Ferrier IN. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia. Journal of Psychiatric Research 2008;42:1037-41.
8. Gallagher P, Watson S, Smith MS, Ferrier IN, Young AH. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biological Psychiatry 2005; Vol. 57, issue 2:155-61.
9. Mackin P, Gallagher P, Watson S, Young AH, Ferrier IN. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Australian and New Zealand Journal of Psychiatry 2007;41(4):321-6.
10. Young A. Mifepristone for bipolar disorder and schizophrenia. Stanley Foundation Research Programs 2009.
11. Marco EJ, Wolkowitz OM, Vinogradov S, Poole JH, Lichtmacher J, Reus VI. Double-blind antiglucocorticoid treatment in schizophrenia and schizoaffective disorder: a pilot study. World Journal of Biological Psychiatry 2002; Vol. 3, issue 3:156-61.
12. Nachshoni T, Ebert T, Abramovitch Y, Asael-Amir MM, Weizman A, Kotler M, et al. The effect of DHEA administration on extrapyramidal symptoms in schizophrenia: a randomized double blind placebo controlled trial. Journal of the European College of Neuropsychopharmacology 2005;15(Suppl 2):S135.
13. Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R, et al. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophrenia Research 2005; Vol. 79, issue 2-3:251-6.
14. Newcomer JW, Craft S, Askins K, Hershey T, Bardgett ME, Csernansky JG, et al. Glucocorticoid interactions with memory function in schizophrenia. Psychoneuroendocrinology 1998; Vol. 23, issue 1:65-72.
15. Ritsner M. Randomized, double-blind, crossover study of dehydroepiandrosterone (DHEA) for schizophrenia. Stanley Foundation Research Programs 2009.
16. Ritsner MS, Gibel A, Ratner Y, Tsinovoy G, Strous RD. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. Journal of Clinical Psychopharmacology 2006; Vol. 26, issue 5:495-9.
17. Ritsner MS, Strous RD. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA. Journal of Psychiatric Research 2010;44:75-80.
18. Strous RD, Gibel A, Maayan R, Weizman A, Ritsner MS. Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover study. Journal of Clinical Psychopharmacology 2008; Vol. 28, issue 4:456-9.
19. NCT00174889. Efficacy and safety of pregnenolone augmentation in the management of schizophrenia patients: a randomised double-blind placebo-controlled trial. https://www.clinicaltrials.gov/ct/show/NCT00174889 (accessed 28 February 2012).
20. Ritsner MS, Gibel A, Shleifer T, Boguslavsky I, Zayed A, Maayan R, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. Journal of Clinical Psychiatry 2010;71(10):1351-62.
21. Strous R, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, et al. Use of dehydro-epiandrosterone in the management of negative symptoms of schizophrenia. Journal of the European College of Neuropsychopharmacology 2002;12(Suppl 3):S286.
22. Strous RD. Dehydroepiandrosterone (DHEA) augmentation in the management of schizophrenia symptomatology. Essential Psychopharmacology 2005;6(3):141-7.
23. Strous RD, Maayan R, Kotler M, Weizman A. Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients. Clinical Neuropharmacology 2005;28(6):265-9.
24. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Archives of General Psychiatry 2003; Vol. 60, issue 2:133-41.
25. Strous RD, Stryjer R, Maayan R, Gal G, Eisner D, Weizman A. Amelioration of symptomatology, Parkinsonism and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in schizophrenia. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S408.
26. Strous RD, Stryjer R, Maayan R, Gal G, Viglin D, Katz E, et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinology 2007; Vol. 32, issue 2:96-105.
27. Barkai AI. Combined electroconvulsive and drug therapy. Comprehensive Therapy 1985; Vol. 11, issue 7:48-53.
28. Beasley CM, Sayler ME, Keisler GM, Potvin JH, Sanger TM, Tollefson GD. The influence of pharamacotherapy on self-directed and externally-directed aggression in schizophrenia. Schizophrenia Research 1998; Vol. 29, issue 1-2:28.
29. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu E-E, Schold C, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biological Psychiatry 2002; Vol. 52, issue 5:386-92.
30. Brambilla F, Bondiolotti G, Maggioni M, Sciascia A, Grillo W, Sanna F, et al. Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory. Neuropsychobiology 1988; Vol. 20, issue 3:113-9.
31. David SR, Meehan KM, Sutton VK, Taylor CC. Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents. Journal of the European College of Neuropsychopharmacology 1999; Vol. 9:S292.
32. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, et al. A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition. Journal of Clinical Psychopharmacology. United States of America, 2004; Vol. 24, issue 1:62-9.
33. Iager A-C, Kirch DG, Bigelow LB, Karson CN. Treatment of schizophrenia with a vasopressin analogue. American Journal of Psychiatry 1986; Vol. 143, issue 3:375-7.
34. Katz PR, Jeste DV, Tariot PN. Pharmacotherapy for the older patient with psychosis. Journal of the American Medical Directors Association 2002;3(4 Suppl 1):H34-7.
35. Kim K. Responses to treatment-refractory chronic schizophrenics to chlorpromazine with concurrent adrenocortical steroid. American Journal of Psychiatry 1960; Vol. 116:1023-4.
36. Kline NS, Blair J, Cooper TB, Esser AH, Hackett E, Vestergaard P. A controlled seven year study of endocrine and other indices in drug treated chronic schizophrenics. Acta Psychiatrica Scandinavica Supplementum 1968; Vol. 206:7-75. [MEDLINE: 4890732]
37. Korsgaard S, Casey DE, Damgaard Pedersen NE, Jørgensen A, Gerlach J. Vasopressin in anergic schizophrenia: a cross-over study with lysine-8-vasopressin and placebo. Psychopharmacology 1981; Vol. 74, issue 4:379-82.
38. Lane HY, Chiu CC, Kazmi Y, Desai H, Lam YW, Jann MW, et al. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. Drug Metabolism & Drug Interactions 2001; Vol. 18, issue 3-4:263-78.
39. Lembke A, Gomez R, Tenakoon L, Keller J, Cohen G, Williams GH, et al. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology 2013;38:115-21.
40. Loranger AW. Treatment of acute mental disorders with an adrenal steroid. British Journal of Psychiatry 1968; Vol. 114, issue 512:843-4. [MEDLINE: 4874165]
41. Miodownik C, Maayan R, Ratner Y, Lerner V, Pintov L, Mar M, et al. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients. Clinical Neuropharmacology 2011;34(4):155-60.
42. Nihalani ND, Schwartz TL. Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression. Current Opinion in Investigational Drugs 2007; Vol. 8, issue 7:563-9.
43. Rees L, King GM. Desoxycortone acetate and ascorbic acid in the treatment of schizophrenia. Journal of Mental Science 1951; Vol. 97:376-80. [MEDLINE: 15780846]
44. Rees L, King GM. Intensive cortisone therapy in schizophrenia. Journal of Mental Science 1956; Vol. 102:155-9.
45. Rothschild AJ. Placebo response in psychotic depression. Journal of Clinical Psychiatry 2005; Vol. 66, issue 12:1615.
46. Schatzberg AF. New approaches to managing psychotic depression. Journal of Clinical Psychiatry 2003; Vol. 64, issue Suppl 1:19-23.
47. Silbergeld S, Noble EP. Corticosteroids in psychiatric patients: subacute and diurnal effects on free fatty acid and catecholamine metabolism. Journal of Psychiatric Research 1973; Vol. 10, issue 1:59-71.
48. Simpson GM, El Sheshai A, Loza N, Kingsbury SJ, Fayek M, Rady A, et al. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. Journal of Clinical Psychiatry 2005; Vol. 66, issue 5:598-602.
49. Stein D, Bannet J, Averbuch I, Landa L, Chazan S, Belmaker RH. Ineffectiveness of vasopressin in the treatment of memory impairment in chronic schizophrenia. Psychopharmacology 1984; Vol. 84, issue 4:566-8.
50. Tollefson GD, Sanger TM. A blinded trial on the course and relationship of depressive symptoms in schizophrenia. Schizophrenia Research 1998; Vol. 29, issue 1, 2:205.
51. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004; Vol. 29, issue 8:1538-45.
52. Hardwick SW, Pearse JJ, Petrow V. 6β-Hydroxy-3:5-Cyclopregnan-20-one in mental states. Journal of Mental Science 1957;103:835-9.
53. Kleiser B, Halberg F, Cornelissen G, Van Valkenburg C. Quantitative chronopharmacodynamic endpoint in health and schizophrenia: timing of plasma dehydroepiandrosterone (DHEA) versus DHEA-sulfate. Annual Review of Chronopharmacology, Proceedings of the 1st International Montreux Conference of Biological Rhythms and Medications; 1984 Mar 26-30; Montreux, Switzerland. Oxford: Pergamon Press, 1984:41-4.
54. Owen M, Victor I, Sophia V, Theresa C, Francesca M, Elysa M, et al. Antiglucocorticoids in depression and schizophrenia. 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9, New York, New York, USA. 1996.
55. Pivac N, Muck-Seler D, Jakovljevic M, Sagud M, Mihaljevic-Peles A, Junaci S. The effects of olanzapine or fluphenazine on peripheral biochemical markers in schizophrenic patients. Proceedings of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 Jun 23-27; Montreal, Canada 2002.
56. Sluchevskii FI, Tikhomirov SM, Bakharev VD. Neuropeptides in the treatment of alcoholism and alcoholic psychoses. Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova 1986;86(2):244-7.
57. Smidt E, Axelsson R, Steen G. Treatment of chronic schizophrenia with glucocorticoids in combination with neuroleptic drugs: a pilot study. Current Therapeutic Research 1988;43:842-50.
58. Volk W, Stoll KD. Double-blind study on the therapy of postural hypotension in psychotic patients under psychotropic medication [Doppelblindversuchzur Therapie Orthostatischer Dysregulationserscheinungen bei Psychotikern unter Psychotroper Medikation]. Arzneimittel-Forschung 1976;26(6):1188-9.
59. Volk W. Hypotonic disorders of circulation regulation caused by therapy with psychotropic drugs. Treatment with 9alpha-fluorhydrocortisone. Medizinische Welt 1977; Vol. 28, issue 45:1853-4.
60. Watson S. The effects of the glucocorticoid receptor antagonist RU-486 in schizophrenia and bipolar disorder. National Research Register 2002; Vol. 1.
61. Jarskog LF. Dehydroepiandrosterone (DHEA) for schizophrenia. Stanley Foundation Research Programs 2009.
62. NCT00725270. Treatment of schizoaffective disorder using mifepristone. https://www.clinicaltrials.gov/ct/show/NCT00725270 (accessed 28 February 2012).
63. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophrenia Research 1997;3:247-51.
64. Altindag A. Lifetime prevalence of psychotic disorders in Finland is 3.1%. Evidence-Based Mental Health 2007;10(3):96.
65. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
66. Alvarez-Jimenez M, Gonzalez-Blanch C, Crespo-Facorro B, Hetrick S, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. Antipsychotic-induced weight gain in schizophrenia spectrum disorders: a systematic critical reappraisal. CNS Drugs 2008;22(7):547-62.
67. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth. Washington: American Psychiatric Association, 2000.
68. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. British Journal of Psychiatry Supplements 1989;7:49-58.
69. Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-6.
70. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
71. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
72. Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Primary Care Companion Journal of Clinical Psychiatry 2001;3(1):17-21.
73. Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale. Canadian Journal of Neurological Science 1980;7:233.
74. Cohrs S, Röher C, Jordan W, Meier A, Huether G, Wuttke W, et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology 2006;185(1):11-8.
75. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town, South Africa. 2000.
76. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
77. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
78. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
79. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials:methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
80. Faustman WO. Brief Psychiatric Rating Scale. The Use of Psychological Testing for Treatment Planning and Outcome Assessment. Mahwah, NJ: Lawrence Erlbaum Associates, 1994:371-401.
81. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
82. Garner B, Pariante CM, Wood SJ, Velakoulis D, Phillips L, Soulsby B, et al. Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. Biological Psychiatry 2005;58(5):417-23.
83. Gerlach J. The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity. Acta Psychiatrica Scandinavica 1993;87:244-52.
84. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
85. Guy W. Early Clinical Drug Evaluation (ECDEU) Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, 1976.
86. Hamilton M. The assessment of anxiety states by rating. British Journal of Psychiatry 1959;32:50-5.
87. Hamilton M. A rating scale for depression. Journal of Neurology and Neurosurgery in Psychiatry 1960;23:56-61.
88. Hedlund JL, Vieweg BW. The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. Journal of Operational Psychiatry 1980;11:48-65.
89. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The quality of life scale; an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10:388-98.
90. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60.
91. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. www.cochrane-handbook.org.
92. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
93. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
94. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
95. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophrenia Bulletin 1999;25(2):201-22.
96. Kerwin RW. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. British Journal of Psychiatry 2004;164(2):141-8.
97. Killackey E, Yung AR. Effectiveness of early intervention in psychosis. Current Opinion in Psychiatry 2007;20(2):121-5.
98. Lammers CH, Garcia-Borreguero D, Schmider J, Gotthardt U, Dettling M, Holsboer F, et al. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biological Psychiatry 1995;38(12):803-7.
99. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001-5. [PUBMED: 16905632]
100. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 1999;35(1):51-68.
101. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
102. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
103. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
104. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 2002;59(10):921-8.
105. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson H. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Australian and New Zealand Journal of Psychiatry 2006;40:616-22.
106. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors. Lancet 1997;349:1436-42.
107. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. American Journal of Psychiatry 1997;154(11):1497-503.
108. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1):1-93.
109. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
110. Pariante CM, Vassilopoulou K, Velakoulis D, Phillips L, Soulsby B, Wood SJ, et al. Abnormal pituitary volume in psychosis. British Journal of Psychiatry 2004;185:5-10.
111. Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry 2007;64(1):19-28.
112. Phillips LJ, McGorry PD, Garner B, Thompson KN, Pantelis C, Wood SJ, et al. Stress, the hippocampus and the HPA axis: implications for the development of psychotic disorders. Austrialian and New Zealand Journal Psychiatry 2006;40:725-41.
113. Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychological Medicine 2002;32(5):763-82.
114. Ryan MCM, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary and renal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 2004;29(8):1065-70.
115. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
116. Sharma RP, Pandey GN, Janicak PG, Peterson J, Comaty JE, Davis JM. The effect of diagnosis and age on the DST - a meta-analytic approach. Biological Psychiatry 1988;24(5):555-68.
117. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11-9.
118. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of cushing's disease. Biological Psychiatry 1999;46(12):1595-602.
119. Thompson KN, Phillips LJ, Komesaroff P, Yuen HP, Wood SJ, Pantelis C, et al. Stress and HPA-axis functioning in young people at ultra high risk for psychosis. Journal of Psychiatric Research 2007;41(7):561-9.
120. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317]
121. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. British Journal of Psychiatry 2004;184:496-502.
122. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
123. Yung AR, Yuen HP, Berger G, Francey S, Hung T, Nelson B, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?. Schizophrenia Bulletin 2007;33:673-81.
124. Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology 2005;30(8):1532-8.